JP2024505195A - 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法 - Google Patents

抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法 Download PDF

Info

Publication number
JP2024505195A
JP2024505195A JP2023544526A JP2023544526A JP2024505195A JP 2024505195 A JP2024505195 A JP 2024505195A JP 2023544526 A JP2023544526 A JP 2023544526A JP 2023544526 A JP2023544526 A JP 2023544526A JP 2024505195 A JP2024505195 A JP 2024505195A
Authority
JP
Japan
Prior art keywords
pdgf
antibody
antigen
antibodies
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544526A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022159875A5 (https=
JP2024505195A5 (https=
Inventor
インリン ガオ，
スコット マクドネル，
バラティ スンダラム，
ジ キム，
プリオレ， イザベラ デル
ジェイク メーニャ
チン ルアン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024505195A publication Critical patent/JP2024505195A/ja
Publication of JPWO2022159875A5 publication Critical patent/JPWO2022159875A5/ja
Publication of JP2024505195A5 publication Critical patent/JP2024505195A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023544526A 2021-01-25 2022-01-25 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法 Pending JP2024505195A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163141030P 2021-01-25 2021-01-25
US63/141,030 2021-01-25
PCT/US2022/013666 WO2022159875A1 (en) 2021-01-25 2022-01-25 Anti-pdgf-b antibodies and mehods of use for treating pulmonary arterial hypertension (pah)

Publications (3)

Publication Number Publication Date
JP2024505195A true JP2024505195A (ja) 2024-02-05
JPWO2022159875A5 JPWO2022159875A5 (https=) 2025-01-30
JP2024505195A5 JP2024505195A5 (https=) 2025-01-30

Family

ID=80446637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544526A Pending JP2024505195A (ja) 2021-01-25 2022-01-25 抗ｐｄｇｆ－ｂ抗体及び肺動脈高血圧症（ｐａｈ）を治療するための使用方法

Country Status (13)

Country Link
US (2) US12030935B2 (https=)
EP (1) EP4281475A1 (https=)
JP (1) JP2024505195A (https=)
KR (1) KR20230135627A (https=)
CN (1) CN116964088A (https=)
AU (1) AU2022210475A1 (https=)
BR (1) BR112023014337A8 (https=)
CA (1) CA3205846A1 (https=)
CL (1) CL2023002148A1 (https=)
CO (1) CO2023010900A2 (https=)
IL (1) IL304505A (https=)
MX (1) MX2023008691A (https=)
WO (1) WO2022159875A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120028552B (zh) * 2025-02-28 2025-08-19 上海交通大学医学院附属上海儿童医学中心 血小板衍生生长因子pdgf-d在评估右心衰竭中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536339A (ja) * 2012-11-09 2015-12-21 ファイザー・インク 血小板由来増殖因子ｂ特異的抗体ならびにこれらの組成物および使用
JP2016504416A (ja) * 2013-01-09 2016-02-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CN107148429B (zh) 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015536339A (ja) * 2012-11-09 2015-12-21 ファイザー・インク 血小板由来増殖因子ｂ特異的抗体ならびにこれらの組成物および使用
JP2016504416A (ja) * 2013-01-09 2016-02-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用

Also Published As

Publication number Publication date
US20220242943A1 (en) 2022-08-04
KR20230135627A (ko) 2023-09-25
CL2023002148A1 (es) 2024-04-12
AU2022210475A1 (en) 2023-08-10
CO2023010900A2 (es) 2023-08-28
US20240425574A1 (en) 2024-12-26
BR112023014337A8 (pt) 2024-03-05
CA3205846A1 (en) 2022-07-28
MX2023008691A (es) 2023-08-01
EP4281475A1 (en) 2023-11-29
US12030935B2 (en) 2024-07-09
CN116964088A (zh) 2023-10-27
BR112023014337A2 (pt) 2023-09-26
IL304505A (en) 2023-09-01
WO2022159875A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
JP6367233B2 (ja) 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用
JP2023175765A (ja) 抗ｃ５抗体及びそれらの使用
JP5701876B2 (ja) ヒトアンジオポイエチン−２に対する高親和性ヒト抗体
US9926369B2 (en) Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody
JP5832435B2 (ja) ヒトプロテアーゼ活性化受容体−２に対する高親和性ヒト抗体
US20180008672A1 (en) Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
AU2013222203B2 (en) Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof
JP2017186347A (ja) 抗ｔｉｅ２抗体およびその使用
JP7438937B2 (ja) 抗ｔｒｋｂモノクローナル抗体および使用の方法
JP7431750B2 (ja) カンナビノイド受容体１型（ｃｂ１）結合性タンパク質及びその使用
JP2024535768A (ja) 抗ｐｖｒｉｇ／ｔｉｇｉｔ二重特異性抗体を含む医薬組成物
JP2019529371A (ja) 肺動脈性肺高血圧を処置するための抗グレムリン−１（ｇｒｅｍ１）抗体およびその使用の方法
JP2024503784A (ja) Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質
US20240425574A1 (en) Anti-pdgf-b antibodies and pharmaceutical composition thereof
KR20240112973A (ko) 길항제 항-npr1 항체 및 이의 사용 방법
CN120437287A (zh) 一种包含特异性结合gucy2c和cd3的双特异性抗体的药物组合物
CN118414354A (zh) 拮抗剂抗npr1抗体及其使用方法
EA044580B1 (ru) Моноклональные анти-trkb антитела и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260305